Roche's $7.1 Billion Telavant Deal Brings Hope for Bowel Disease Treatment
Swiss pharmaceutical company Roche has announced its acquisition of Telavant, an immunology company developing a potential treatment for inflammatory bowel disease, in a deal worth over $7 billion. The deal grants Roche the rights to develop and commercialize Telavant's experimental antibody therapy, RVT-3101, in the United States and Japan. Roche plans to conduct Phase 3 clinical trials for the therapy and collaborate with Pfizer to develop a "next generation" antibody therapy for inflammatory bowel disease. The acquisition aims to strengthen Roche's drug pipeline following several late-stage failures in 2020.